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Anthranilic Acid Derivatives as Novel Antibiotics against MRSA and other
Gram Positive Microorganisms: Combating Antibiotic Resistance
ABSTRACT

Nkrumah Grant
McNair Scholar

Roderick Morgan, Ph.D.
Faculty Mentor

Implementation of antibiotics to treat
bacterial infections began during World
War II. Since then, a number of antibiotic
resistance microorganisms have emerged,
one of these being Methicillin Resistant
Staphylococcus aureus (MRSA). This
resistance can be accredited to multiple
factors, but the greatest contributors are the
similarity in the chemical composition of
the commonly prescribed antibiotics used
to treat MRSA and the improper use and
disposal of these agents. MRSA is the most
frequent health acquired infection in the
United States and to combat this growing
problem, we have developed a novel class
of antibiotics derived from anthranilic
acids that show antibacterial activity
against MRSA. Our derivatives record a
minimum inhibitory concentration (MIC)
ranging from 2-64 µg/ml, however when
in the presence of human serum protein
(HSP) this value increases, decreasing
their effectiveness. We have identified a
component of HSP, albumin, that causes
the increase in MIC, and have determined
that intermolecular hydrogen bonding
is the cause of this increase. Using this
information we are currently synthesizing
new derivatives with a low binding affinity
for albumin, or when bound do not lose
antibacterial activity.
INTRODUCTION
In 1929 a microbiologist by the name
of Alexander Flemming accidentally
contaminated a microbial sample with the
fungus Penicillium. After incubating the
media for growth, he found that in areas
where fungal growth was observed, bacterial
growth was inhibited. By the year 1940 the
antimicrobial properties of the fungus were
investigated and then made available for
medical use under the trade name penicillin
(1). Penicillin functions as an exogenous
metabolite belonging to the antibiotic family
known as β-Lactams. Implemented into
the health care system in the latter years of
WWII, β-Lactams are still the most widely
prescribed antibiotics in the world today.
The effectiveness of the medications derived

from this chemical class is attributed to
its ability to inhibit the bacterial enzyme
transpeptidiase. This enzyme is required to
form crosslinks between the sugars of the
peptidoglycan layers, a mechanism that
inevitably leads to the formation of a viable
bacterial cell wall (2).
As penicillin became widely used, a strain
of Staphylococcus aureus was found to have
conferred resistance to the antibiotic,
and in 1959, methicillin, a synthetic
variation of penicillin was introduced
(as a member of the β-Lactam class) to
ward off these infections. The longevity
of its effectiveness only lasted two years,
and in 1961 the first case of MethicillinResistant Staphylococcus aureus (MRSA)
was described in the United Kingdom (3),
with the first case reported in the United
States in 1968 (4). In the years following
its observance in the United States, studies
involved with the isolation of MRSA in
hospitals found that between 1975 and
1980 there was an increase in the number
of isolates amounting to 467% (4).
Although infectious diseases, particularly
those caused by bacterial microorganisms,
are still among the top causes of mortality
in the world, pharmaceutical support
for the development of novel antibiotics
against them continue to decline.
Furthermore, when novel antibiotics
are developed, they are introduced as
modified derivatives of compounds already
known to be effective (5). This practice
has inadvertently become problematic;
the lack of novel antibiotics to reduce
natural selection and beneficial mutations
in bacterial microorganisms has led to the
emergence of antibiotic resistant organisms
including MRSA, Vancomycin Resistant
Enterococci (VRE), and Extreme Drug
Resistant Tuberculosis (XDR-TB). Of
these microorganisms, MRSA accounts
for 1.9 million infections, 99,000 deaths,
and health care costs amounting to over 5
billion dollars annually, and is the number
one health acquired infection in the United
States (6). It is for these societal concerns
that novel antibiotics are generated, but
this is a trivial task.
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In addition to the inherent costs associated
with drug development, there are multiple
intermolecular interactions that occur
in vivo between drug and host that must
be taken into account including drug
toxicity, dosage, and excretion. A major
contributor to these interactions is the
well-studied protein component of human
serum, albumin. Accounting for 65% of
serum composition, albumin functions as a
transporter for fatty acids and endogenous
and exogenous metabolites (7). Research
has shown that albumin drug binding
occurs primarily at two “Sudlow” sites
located in subdomains IIA (site 1) and IIIA
(site II) of the protein; as a result, binding
sequesters the compounds deeming them
inactive (8)which is yet another deterrent
in developing novel drugs. However, as
the advent of MRSA and other resistant
microorganisms have emerged, the demand
for new antibacterial reagents has caught
the interest of pharmaceutical companies
once again.

generated to test for antibacterial activity.
The anthranilic acid derivatives were
dissolved at .01g each in 0.2 ml DMSO
and 0.8 ml of 0.1 molar KOH equating
to a final concentration of 10µg/ml. Using
Staphylococcus aureus and Escherichia coli,
the effectiveness of the compounds were
analyzed for antimicrobial activity by
employing the Kirby-Bauer disk diffusion
method (CLSI; 9, 10). Ten microliters of
each test compound was added to the 6
mm sterile disks, followed by incubation
at 35.7°C for 18-24 hours to stimulate
bacterial growth. Our standard derivative,
GV-2 (Fig. 1) was used as a positive control
and was added at the same volume and
concentration. After incubation, the agar
plates were inspected and the zones of
inhibition were measured. For each active
compound, the minimum inhibitory
concentration (MIC) was determined
using standard microdilution protocol as
prescribed by the Clinical and Laboratory
Standards Institute (CLSI; 9, 10).

To ensure a representative simulation,
SwissDock runs a thorough check on the
target protein and ligand(s) before running
an assay (11). During this investigation,
if any aspect of the protein structure is
incomplete or defective and if the topology
and tautomeric form of the ligand is
incorrect, the assay is rejected (4, 11). The
albumin structure we selected was found
to have 39 missing residues (http://www.
rcsb.or/pdb/files/2BXN.pdb). To correct
this issue, the structure was patched
using the Visual Molecular Dynamic
software package. We generated our ligand
(GV-2) using the Avogadro interface to
ensure that the ligand met the criteria for
the simulation. After completing these
manipulations, albumin and GV-2 were
uploaded into SwissDock and was accepted
for the assay. The docking parameters were
set to an accurate screening of the entire
protein with a flexibility range within 3Å
of any atom of the ligand in its reference
binding mode.

In contribution to this increased interest,
our research group has developed a novel
class of antibiotics derived from anthranilic
acids. Our class varies in effectiveness with
many compounds showing antibacterial
activity in vitro at a minimum inhibitory
concentration (MIC) ranging between
2-64 µg/ml; however, when in the presence
of human serum protein (HSP) this value
increases, decreasing their antibacterial
activity. We have targeted albumin as the
probable protein target responsible for
this inactivating interaction. Our research
group hopes to verify the role of albumin
in the sequestration and inactivation of
our novel antibiotics using computational
biology software. By deducing if and how
our compounds bind to albumin, we
hope to use this information to develop
derivatives with a lower binding affinity
for HSP, or when bound do not lose
antibacterial activity. If successful, the
engenderment of such derivatives will
add to the treatment options available
to combat bacterial infections including
MRSA, reducing antibiotic resistance
and the costs associated with treatments
currently administered.

Albumin binding. Any compound with
an MIC ≤ 64µg/ml was tested in a second
MIC assay with the addition of 10%
HSP to determine if serum inactivation
was observed. To assess albumin binding,
bovine serum albumin (BSA) was prepared
at 20%, 10%, and 5% concentrations
(final concentrations 2%, 1%, .05%) in
autoclaved 18 M Ohms dH2O solvent and
was substituted for HSP in the dilution
series using our standard test compound
GV-2. BSA was used for the analysis based
on a 76.36% sequence alignment between
the BSA protein structure and Human
Serum Albumin (HSA).

RESULTS

METHODS
Antibacterial activity determination.
Twenty two novel antibiotics were
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In order to determine whether our
compounds were binding to albumin, the
online docking server at http://swissdock.
ch was used. SwissDock is a free web service
that determines the most probable binding
interactions taking place between a target
protein and ligand based on the EADock
DSS algorithm (11). Only three steps are
required to start a docking assay: 1) users
define a target protein, 2) a ligand is selected
from the comprehensive list supplied or
from one that has been uploaded by the
user, and 3) the docking parameters are
set (11). The target protein for our assay,
albumin (PDB: 2BXN), was obtained from
the RCSB Protein Data Bank.

Of the 22 compounds that were
synthesized, 13.6% showed antibacterial
activity against Staphylococcus aureus
(Table 1). Of those that showed activity,
compound KU1-1-A had the greatest
efficiency with a MIC equating to 16µg/
ml. A secondary screening for antibacterial
activity completed in 10% human serum
protein on compounds with a MIC ≤
64µg/ml showed an increase in the initial
MIC recorded (Table 1). The results
from the BSA MIC assay demonstrated
that GV-2 did bind to albumin and its
inactivation was concentration dependent
upon the protein (Table 2). Thereafter,
HSA was obtained from Sigma Aldrich
and a MIC assay conducted using HSA
demonstrated results that were consistent
with that of BSA’s MIC results (Table 2).
After this determination had been made,
and the GV-2/albumin targets were
uploaded into the SwissDock web interface,
the output file of the binding interactions
between GV-2 and albumin was visualized
using Chimera 1.8 (12), which verified
binding was occurring (Fig. 2). Binding
interactions were considered significant if
the interactions between atoms of GV-2
and the molecules of albumin were within
2 Å. Based upon this criterion, analysis

showed that the binding mode for the
interactions between GV-2 and albumin is
primarily due to intermolecular hydrogen
bonding (Fig. 2) between the carboxylic
acid functional group of the aromatic
ring and the side chain residues spanning
albumin in the region associated with both
drug site I and II, with more interactions
occurring within drug site II (Table 3).
After analyzing the binding data, it was
proposed that coupling GV-2 would lead
to a compound that was not inactivated
in vivo. The theory was that coupled
derivative would bind albumin while
leaving the other end free and active,
assuming a second albumin protein
molecule was unable to bond the free
end due to unfavorable electrostatic
interactions. Five compounds meeting this
structural proposition were synthesized by
varying the chain length in the aliphatic
region of GV-2, which was then coupled to
another molecule of the same makeup (Fig.
3). The results of the disk diffusion assay
did not uphold the proposition in that no
antibacterial activity was observed.
DISCUSSION
It is well documented that binding to HSA
controls the free, active concentration of
a drug, provides a repository for a long
duration of action, and ultimately affects
drug absorption, metabolism, distribution
and excretion (8). At one time these
interactions were a major deterrent in
generating novel drugs because of the
unknown role of albumin on drug binding;
however, the advancements that have been
made in bioinformatics has revealed the
mechanisms of action for albumin binding
and in effect has increased pharmaceutical
interests. With the information obtained
from such molecular investigations, drug
developers have been able to exploit
albumin’s high binding affinity for anionic
and hydrophobic fatty acid compounds.
This has led to the anchoring of novel
pharmaceuticals to albumin binding
molecules utilizing the protein’s carrier
capabilities and also to effective dosage
schedules empirically devised for highly
albumin – bound drugs (8).
The bioinformatics approach we have
added to our study has also provided our
team with some insightful information.
Research conducted in our lab in the

years preceding this investigation has
shown that removal of the carboxylic
acid functional group on the anthranilic
core deems the synthesized derivatives
inactive - results aligning with the
information obtained from the binding
analysis conducted in this study. Further
analysis of the drug site for which GV-2
binding was most favorable was also of
importance; the hydrophobicity of the
binding cavity and the positively charged
pocket entrance creates an environment
that is attractive to the anionic, fatty acid
chemical makeup of GV-2 and most of
our derivatives. This information was
unknown and with its revelation our team
is synthesizing derivatives by modifying the
hydrophobicity and hydrophilicity of GV-2
in an effort to create derivatives with a
decreased binding affinity for HSP or when
bound that do not lose its antibacterial
activity. Although the five compounds we
have synthesized reflecting the change did
not show any antibacterial activity, we
believe the reason to be because they were
not in concordance with the weight limit
of antibacterial compounds prescribed by
Lipinski’s rule of five, and we are currently
making modifications so that these criteria
are met.

attributed to MRSA has seen a steady
increase worldwide and is not only a
common HAI but has also become a
common community acquired infection
as well. The decreasing availability of
antibiotics once effective in treating MRSA
increases the potential for more deadly
encounters with the superbug. Modifying
our class of compounds so that they do not
lose antibacterial activity in vivo, would
allow their implementation into the health
care system, which will effectively decrease
morbidity and the amount of money spent
on treating infections caused by MRSA
and other antibiotic resistant organisms
worldwide.

In contrast to the positive information
provided by the protein docking assay the
SwissDock interface has its limitations.
Due to the complexities associated with
predicting the binding affinity between
ligands and targets, SwissDock does
not provide this type of data; without
having such information, alternative
intermolecular interactions that may be
contributing to GV-2 inactivation, such
as, Van Der Wall forces or ionic bonding
has not been accounted for in this study.
Furthermore, the interface predicts binding
for one ligand at a time. This may not be
a true representation of what is occurring
in vivo due to albumin’s ability to bind
more than one ligand simultaneously
by exposing other putative binding sites
within the protein. Although these areas
have not been addressed in this study,
these limitations do not negate the results
obtained in that many drug developers
have found success using SwissDock and
similar docking servers.
The implications of our research endeavors
are far reaching. The amount of infections
9
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FIGURES & DATA TABLES

Fig. 1. Chemical structure of GV-2 (5-bromo-2-[(2E)-non-2-enoylamino] benzoic acid).

Fig. 2. A depiction of GV-2 bound to human serum albumin between the carboxylic acid functional group
and albumin side chain residues by means of intermolecular hydrogen bonding.

Fig. 3. Proposition for new chemical derivative based on the coupling of GV-2
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Table 1. Antibacterial activity of GV-2 chemical derivatives against Staphylococcus aureus. The zone of inhibition was measured on
MH agar plates and the minimum inhibitory concentration was determined in the absence or presence of 10% human serum protein.

Table 2. MIC of GV-2 in the presence of bovine and human serum albumin at 2%, 1% and 0.05% concentrations. Human serum
protein was not subjected to testing at 2% and 1% concentrations because of our interest in comparing the lowest concentration of
bovine serum albumin that produced a MIC < 256 µg/ml.

Table 3. Binding interactions occurring within 2 Å of albumin side chain residues and atoms of GV-2 as determined using
SwissDock interface and Chimera 1.8.
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